^
6ms
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov)
P1, N=94, Active, not recruiting, Arcus Biosciences, Inc. | Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: Jan 2025 --> Sep 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Yutuo (zimberelimab) • ralzapastotug (AB308)
9ms
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov)
P1, N=94, Active, not recruiting, Arcus Biosciences, Inc. | Trial completion date: Jan 2024 --> Mar 2025 | Trial primary completion date: Jan 2024 --> Mar 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Yutuo (zimberelimab) • ralzapastotug (AB308)
over1year
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov)
P1, N=107, Recruiting, Arcus Biosciences, Inc. | Trial completion date: Dec 2023 --> Jul 2025 | Trial primary completion date: Jun 2023 --> Jul 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Yutuo (zimberelimab) • ralzapastotug (AB308)
3years
ARC-12: Phase 1/1b Study to Evaluate Safety and Tolerability of AB308 + Zimberelimab (AB122) in Advanced Malignancies (ASH 2021)
Safety and efficacy data will be analyzed using summary statistics and Kaplan Meier estimates as appropriate; PK parameters will be estimated using noncompartmental methods. ARC-12 is actively recruiting at sites in the United States (NCT04772989).
Clinical • P1 data
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
Yutuo (zimberelimab) • ralzapastotug (AB308)
over3years
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov)
P1, N=154, Recruiting, Arcus Biosciences, Inc. | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Yutuo (zimberelimab) • ralzapastotug (AB308)
over3years
Clinical • New P1 trial • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Yutuo (zimberelimab) • ralzapastotug (AB308)